After a totally crazy last week, I must say it’s a tremendous relief to get back to focusing on science and early stage clinical development!
Behind the all the ongoing political and Covid-19 furore, the ASH abstracts dropped unexpectedly early on November 4th instead of Bonfire Night and this week it’s the start of the SITC meeting with live presentations already starting.
Every year we post a series of Previews highlighting key data to watch out for on key selected topics. The focus varies with each meeting with a look at different targets, modalities, or tumour types. This year we’re kicking off our coverage with a focused look at bispecific antibodies in early development…
Are bispecifics flying high at ASH20?
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our first meeting Preview of 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
Cherry Blossoms and Iwakuni Bridge
We’re continuing our countdown to the 2016 AACR annual meeting in New Orleans with a look at anti TIM-3 and LAG-3 inhibitory checkpoints and highlighting some of the companies with noteworthy abstracts.
In case you missed it, yesterday AACR announced that Vice President Biden will be delivering remarks on the final day of the meeting, Wednesday, April 20th in the “Highlights 2016: Vision for the Future” Plenary Session. As conference diehards, we will be there in person, but AACR have announced they plan to livestream it to the world. It’s a fitting finale to what is set to be a “must attend” meeting for those with an interest in cancer new product development and in particular, cancer immunotherapy.
What can we learn from AACR abstracts on TIM–3 and LAG–3?
There is some early clinical data that we will be checking out (no pun intended) on TIM-3 and LAG-3.
Subscribers can read Day 2 of our “Road to AACR 2016” coverage by logging in, or you can purchase access.